Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 107Gynecologic 5Genitourinary 2Tumor-Agnostic 1Thoracic 1Other neoplasm 1Gastrointestinal 1Endocrine 1

Conditions

Prostatic Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × exemestane × Genitourinary × Clear all
NCT06630325 2026-04-28

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Terminated
6 enrolled 3 charts
GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT00031889 2012-05-15

Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer

Swiss Cancer Institute

Phase 2 Completed
5 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡